[go: up one dir, main page]

PE20090606A1 - Nuevos inhibidores de catepsina c y uso - Google Patents

Nuevos inhibidores de catepsina c y uso

Info

Publication number
PE20090606A1
PE20090606A1 PE2008001403A PE2008001403A PE20090606A1 PE 20090606 A1 PE20090606 A1 PE 20090606A1 PE 2008001403 A PE2008001403 A PE 2008001403A PE 2008001403 A PE2008001403 A PE 2008001403A PE 20090606 A1 PE20090606 A1 PE 20090606A1
Authority
PE
Peru
Prior art keywords
alkyl
catepsin
inhibitors
benzenosulfonamide
pyrrolidinyl
Prior art date
Application number
PE2008001403A
Other languages
English (en)
Inventor
Jianghe Deng
Laine Dramane Ibrahim
Michael R Palovich
Haibo Xie
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20090606A1 publication Critical patent/PE20090606A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE R1 ES HALO, ALQUILO C1-C4, CF3, CN, NO2, ENTRE OTROS; n ES 0-4; R2a ES H, HALO, CO(ALQUILO C1-C4), COO-FENILO, ENTRE OTROS; R2b ES H, ALQUILO C1-C4; R2c ES H, ALQUILO C1-C4; R3 ES H, ALQUILO C1-C4, CICLOALQUILO C3-C6, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: 2,5-DIBROMO-N-[(3R,5S)-1-CIANO-5-METIL-3-PIRROLIDINIL]BENCENOSULFONAMIDA; N-[(3R,5S)-1-CIANO-5-METIL-3-PIRROLIDINIL]-2,5-BIS(METILOXI)BENCENOSULFONAMIDA; 2-BROMO-N-[(3R,5S)-1-5METIL-3-PIRROLIDINIL]-5-(TRIFLUOROMETIL)BENCENOSULFONAMIDA; ENTRE OTROS. REFERIDA ADEMAS A UNA COMPOSICION FARMACEUTICA Y UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE CATEPSINA C, UTILES EN EL TRATAMIENTO DE EPOC
PE2008001403A 2007-08-20 2008-08-18 Nuevos inhibidores de catepsina c y uso PE20090606A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US95674407P 2007-08-20 2007-08-20

Publications (1)

Publication Number Publication Date
PE20090606A1 true PE20090606A1 (es) 2009-06-17

Family

ID=40378560

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008001403A PE20090606A1 (es) 2007-08-20 2008-08-18 Nuevos inhibidores de catepsina c y uso

Country Status (7)

Country Link
US (1) US20090264431A1 (es)
AR (1) AR067978A1 (es)
CL (1) CL2008002430A1 (es)
PE (1) PE20090606A1 (es)
TW (1) TW200922556A (es)
UY (1) UY31299A1 (es)
WO (1) WO2009026197A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011011428A (es) * 2009-05-01 2011-11-29 Raqualia Pharma Inc Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
ES2513291T3 (es) 2009-10-29 2014-10-24 Janssen Pharmaceutica Nv Derivados alquinilo útiles como inhibidores de la DPP-1
EP2471363A1 (de) 2010-12-30 2012-07-04 Bayer CropScience AG Verwendung von Aryl-, Heteroaryl- und Benzylsulfonamidocarbonsäuren, -carbonsäureestern, -carbonsäureamiden und -carbonitrilen oder deren Salze zur Steigerung der Stresstoleranz in Pflanzen
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
GB201521109D0 (en) 2015-11-30 2016-01-13 Mission Therapeutics Ltd Novel compounds
GB201603779D0 (en) 2016-03-04 2016-04-20 Mission Therapeutics Ltd Novel compounds
GB201616511D0 (en) 2016-09-29 2016-11-16 Mission Therapeutics Limited Novel compounds
WO2018108627A1 (de) 2016-12-12 2018-06-21 Bayer Cropscience Aktiengesellschaft Verwendung substituierter indolinylmethylsulfonamide oder deren salze zur steigerung der stresstoleranz in pflanzen
GB201708652D0 (en) 2017-05-31 2017-07-12 Mission Therapeutics Ltd Novel compounds and uses
EP3642196B1 (en) 2017-06-20 2022-08-17 Mission Therapeutics Limited Substituted cyanopyrrolidines with activity as dub inhibitors
WO2019025153A1 (de) 2017-07-31 2019-02-07 Bayer Cropscience Aktiengesellschaft Verwendung von substituierten n-sulfonyl-n'-aryldiaminoalkanen und n-sulfonyl-n'-heteroaryldiaminoalkanen oder deren salzen zur steigerung der stresstoleranz in pflanzen
GB201905375D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201905371D0 (en) 2019-04-16 2019-05-29 Mission Therapeutics Ltd Novel compounds
GB201912674D0 (en) 2019-09-04 2019-10-16 Mission Therapeutics Ltd Novel compounds
EP4132925A1 (en) 2020-04-08 2023-02-15 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
US20230219939A1 (en) 2020-05-28 2023-07-13 Mission Therapeutics Limited N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mitochondrial dysfunction
US20230303547A1 (en) 2020-06-04 2023-09-28 Mission Therapeutics Limited N-cyanopyrrolidines with activity as usp30 inhibitors
MX2022015608A (es) 2020-06-08 2023-03-03 Mission Therapeutics Ltd Hexahidropirrolo[3,4-b]pirrol-5(1h)-carbonitrilos con actividad como inhibidores de la peptidasa especifica de ubiquitina 30 (usp30).
GB202016800D0 (en) 2020-10-22 2020-12-09 Mission Therapeutics Ltd Novel compounds
EP4441044A1 (en) 2021-12-01 2024-10-09 Mission Therapeutics Limited Substituted n-cyanopyrrolidines with activity as usp30 inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2404630A1 (en) * 2000-04-06 2001-10-18 Merck Frosst Canada & Co. Cathepsin cysteine protease inhibitors
US7736875B2 (en) * 2000-09-08 2010-06-15 Prozymex A/S Dipeptidyl peptidase I crystal structure and its uses
EP1858509A4 (en) * 2005-03-02 2009-03-18 Glaxo Group Ltd NEW CATHEPSIN C HEMMER AND ITS USE

Also Published As

Publication number Publication date
AR067978A1 (es) 2009-10-28
TW200922556A (en) 2009-06-01
US20090264431A1 (en) 2009-10-22
WO2009026197A1 (en) 2009-02-26
CL2008002430A1 (es) 2009-10-16
UY31299A1 (es) 2009-03-31

Similar Documents

Publication Publication Date Title
PE20090606A1 (es) Nuevos inhibidores de catepsina c y uso
PE20091577A1 (es) Inhibidores de cinasa pim y metodos para su uso
PE20090727A1 (es) DERIVADOS DE AMIDA COMO INHIBIDORES DE NaV1.7
PE20091556A1 (es) Derivado heterociclico fusionado y su uso
PE20211700A1 (es) Compuesto heterociclico y su uso
PE20090434A1 (es) Derivados de sulfonil amida como inhibidores de quinasas
PE20080906A1 (es) Derivados heteroarilo como inhibidores de citocina
PE20141700A1 (es) Compuestos de 2-(2,4,5-anilino sustituido) pirimidina
PE20110062A1 (es) N-(3-(3,5-dimetoxifenetil)-1h-pirazol-5-il)-4-(3,4-dimetilpiperazin-1-il)benzamida y sales del mismo
EA201171333A1 (ru) Кристаллические сольваты и комплексы производных (1s)-1,5-ангидро-1-с-(3-((фенил)метил)фенил)-d-глюцитола с аминокислотами в качестве ингибиторов sglt2 для лечения диабета
PE20121354A1 (es) Inhibidores del virus de la hepatitis c
PE20121335A1 (es) Compuestos derivados de amida como inhibidores de raf cinasas
PE20110150A1 (es) Amidofenoxiindazoles como inhibidores de c-met
PE20090772A1 (es) Derivados de bencimidazol
PE20110308A1 (es) 1,2,5-oxadiazoles como inhibidores de indolamina 2,3-dioxigenasa
PE20081354A1 (es) Compuestos de azaindolilo como inhibidores de mek
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
PE20091573A1 (es) Derivados heterociclicos de urea como inhibidores de adn girasa y/o topoisomerasa
PE20090837A1 (es) Nuevos compuestos quimicos
PE20091092A1 (es) Compuestos heterociclicos como inhibidores de la via hedgehog
PE20091201A1 (es) AMIDAS SUSTITUIDAS COMO INHIBIDORES DE LA TIROSINA QUINASA DE BRUTON (Btk)
PE20120355A1 (es) DERIVADOS DE PIRAZOL COMO INHIBIDORES DE LA ENZIMA 11ßHSD1
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
PE20070593A1 (es) Compuestos pirrolopirimidina como inhibidores de syk
PE20091002A1 (es) Analogos dipeptidos como inhibidores del factor de coagulacion

Legal Events

Date Code Title Description
FC Refusal